Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 21, 2021 - Issue 11
Submit an article Journal homepage
373
Views
0
CrossRef citations to date
0
Altmetric
Meeting report

2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma

Roberto Iacovellia Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyCorrespondence[email protected]
View further author information
,
Maria Antonella Cannellaa Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyView further author information
,
Chiara Ciccaresea Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy;b Department of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information
,
Serena Astorea Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyView further author information
,
Nazario Foschic Department of Urology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyView further author information
,
Giuseppe Palermoc Department of Urology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyView further author information
&
Giampaolo Tortoraa Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy;b Department of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyView further author information
 show all
Pages 1203-1206 | Received 30 Apr 2021, Accepted 24 Aug 2021, Published online: 09 Sep 2021

References

  • Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290.
  • Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–1127.
  • Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–1115.
  • Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841.
  • Motzer RJ, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–1300.
  • Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin Oncol. 2021;39(suppl 6):abstr 308.
  • Cella D, Choueiri TM, Blum SI, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with first-line nivolumab plus cabozantinib versus sunitinib: the CheckMate 9ER trial. J Clin Oncol. 2021;39(suppl. 6):Abstract 285.
  • Ciccarese C, Iacovelli R, Brunelli M, et al. Addressing the best treatment for non-clear cell renal cell carcinoma: a meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer. 2017;83:237–246.
  • Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016 Jan 14;374(2):135–145.
  • Pal SK, Tangen C, Thompson IM, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703.
  • ESMO Guidelines Committee, Powles T. Electronic address: [email protected]. Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):422–423.
  • Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108:33–40.
  • Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 Jun;114:67–75.
  • Ornstein MC, Pal SK, Wood LS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019;20:1386–1394.
  • Ravi P, Mantia C, Su C, et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol. 2020;6(10):1606–1610.
  • Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112–117.
  • Martínez-S O, Gajate P, Alonzo-Gordoa T, et al. Targeting HIF-2 α in clear cell renal cell carcinoma: a promising therapeutic strategy. Crit Rev Oncol Hematol. 2017;111:117–123.
  • Choueiri TK, Plimack ER, Bauer TM, et al. Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J Clin Oncol. 2020;38(6_suppl): 611–611. DOI:https://doi.org/10.1200/JCO.2020.38.6_suppl.611.
  • Bauer TM, Choueiri TK, Papadopoulos KP, et al. The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(suppl. 6):Abstract 273.
  • Choueiri TK, Bauer TM, McDermott DF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(suppl. 6):Abstract 272.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.